{"hands_on_practices": [{"introduction": "The foundation of modern oncology is a precise diagnosis that integrates histopathology with molecular genetics. This is especially true in rhabdomyosarcoma, where genetic fusion status is a powerful prognostic marker. This exercise demonstrates how to quantitatively update diagnostic certainty using Bayesian principles when faced with equivocal data, a critical skill for interpreting ancillary tests like FISH in the context of a prior immunophenotype. [@problem_id:4445998]", "problem": "A pediatric soft tissue tumor shows skeletal muscle differentiation. In the pathology workup, immunohistochemistry (IHC) demonstrates strong, diffuse nuclear staining for myogenin at 3+ intensity in >80% of tumor cells, while desmin is negative. Histomorphology is equivocal between embryonal and alveolar patterns. In this discordant IHC setting, molecular confirmation of a forkhead box O1 (FOXO1) gene rearrangement characteristic of fusion-positive alveolar rhabdomyosarcoma (RMS) is considered. Institutional data for this specific immunophenotypic subset indicate a pretest prevalence $p=0.30$ for fusion-positive alveolar RMS. A dual-color break-apart fluorescence in situ hybridization (FISH) assay for FOXO1 rearrangement has sensitivity $S_{e}=0.95$ and specificity $S_{p}=0.99$. The FISH assay returns a positive result.\n\nStarting from core definitions of sensitivity, specificity, and conditional probability, and without invoking any unintroduced shortcut formulas, compute the post-test probability that the tumor is fusion-positive alveolar RMS given the positive FISH result. Round your answer to four significant figures and express it as a decimal. Also, briefly justify, based on foundational pathology principles, why pursuing fusion testing is indicated in the setting of strong myogenin with negative desmin.", "solution": "The problem is valid as it is scientifically grounded in the principles of pathology and biostatistics, is well-posed with all necessary information provided, and is expressed in objective, unambiguous language.\n\nThe solution consists of two parts: a quantitative calculation of the post-test probability and a qualitative justification for performing the molecular test based on pathology principles.\n\n**Part 1: Calculation of Post-Test Probability**\n\nThe task is to compute the post-test probability that the tumor is fusion-positive alveolar rhabdomyosarcoma (RMS), given a positive result from the fluorescence in situ hybridization (FISH) assay. This is a problem of Bayesian inference. We will derive the solution from the foundational definitions of conditional probability, sensitivity, and specificity.\n\nFirst, let us define the relevant events:\n-   Let $F+$ be the event that the tumor is fusion-positive alveolar RMS.\n-   Let $F-$ be the event that the tumor is *not* fusion-positive alveolar RMS.\n-   Let $T+$ be the event that the FISH assay for FOXO1 rearrangement is positive.\n-   Let $T-$ be the event that the FISH assay is negative.\n\nFrom the problem statement, we are given the following probabilities:\n-   The pre-test probability, or prevalence, of fusion-positive alveolar RMS in this specific immunophenotypic subset is $P(F+) = p = 0.30$.\n-   The probability of the tumor not being fusion-positive is therefore $P(F-) = 1 - P(F+) = 1 - 0.30 = 0.70$.\n-   The sensitivity of the FISH assay is $S_{e} = P(T+ | F+) = 0.95$. This is the probability of a positive test result given that the tumor is indeed fusion-positive.\n-   The specificity of the FISH assay is $S_{p} = P(T- | F-) = 0.99$. This is the probability of a negative test result given that the tumor is not fusion-positive.\n\nFrom the specificity, we can deduce the false positive rate, which is the probability of a positive test result given that the tumor is not fusion-positive:\n$$P(T+ | F-) = 1 - S_{p} = 1 - P(T- | F-) = 1 - 0.99 = 0.01$$\n\nOur goal is to calculate the post-test probability, $P(F+ | T+)$, which is the probability that the tumor is fusion-positive given that the FISH assay returned a positive result.\n\nWe begin with the definition of conditional probability:\n$$P(F+ | T+) = \\frac{P(F+ \\cap T+)}{P(T+)}$$\nwhere $P(F+ \\cap T+)$ is the joint probability of the tumor being fusion-positive and the test being positive.\n\nThe numerator, $P(F+ \\cap T+)$, can be re-expressed using the definition of conditional probability, $P(T+ | F+) = \\frac{P(F+ \\cap T+)}{P(F+)}$. Rearranging this gives:\n$$P(F+ \\cap T+) = P(T+ | F+) P(F+)$$\nThis term represents the probability of a true positive result.\n\nThe denominator, $P(T+)$, is the total probability of obtaining a positive test result. A positive test can occur in two mutually exclusive scenarios: a true positive (the tumor is fusion-positive, and the test is positive) or a false positive (the tumor is not fusion-positive, but the test is positive). Using the law of total probability, we can write $P(T+)$ as the sum of the probabilities of these two scenarios:\n$$P(T+) = P(T+ \\cap F+) + P(T+ \\cap F-)$$\nApplying the same rearrangement as above to each term, we get:\n$$P(T+) = P(T+ | F+) P(F+) + P(T+ | F-) P(F-)$$\n\nSubstituting the expressions for the numerator and the denominator back into our main equation for $P(F+ | T+)$, we arrive at Bayes' theorem:\n$$P(F+ | T+) = \\frac{P(T+ | F+) P(F+)}{P(T+ | F+) P(F+) + P(T+ | F-) P(F-)}$$\n\nNow, we substitute the given numerical values into this formula:\n-   $P(F+) = 0.30$\n-   $P(F-) = 0.70$\n-   $P(T+ | F+) = 0.95$\n-   $P(T+ | F-) = 0.01$\n\n$$P(F+ | T+) = \\frac{(0.95)(0.30)}{(0.95)(0.30) + (0.01)(0.70)}$$\nFirst, we calculate the numerator and the terms in the denominator:\n-   Numerator: $0.95 \\times 0.30 = 0.285$\n-   Denominator term 1 (true positives): $0.95 \\times 0.30 = 0.285$\n-   Denominator term 2 (false positives): $0.01 \\times 0.70 = 0.007$\n\nThe total probability of a positive test is the sum of these denominator terms:\n$$P(T+) = 0.285 + 0.007 = 0.292$$\nFinally, we compute the post-test probability:\n$$P(F+ | T+) = \\frac{0.285}{0.292} \\approx 0.976027397...$$\nRounding the result to four significant figures as requested, we obtain $0.9760$.\n\n**Part 2: Justification for Fusion Testing**\n\nPursuing molecular confirmation with a FOXO1 FISH assay is clinically and pathologically indicated in this scenario for several fundamental reasons:\n\n1.  **Resolution of Diagnostic Ambiguity:** The provided laboratory data present a picture that is highly suggestive but not entirely conclusive.\n    -   **IHC Discordance:** Myogenin is a highly specific nuclear transcription factor for skeletal muscle lineage and its strong, diffuse positivity is a cornerstone for the diagnosis of rhabdomyosarcoma (RMS). However, desmin, an intermediate filament protein, is typically also positive in most RMS cases. The finding of negative desmin is atypical or \"discordant,\" raising a minor question about the tumor's exact phenotype, even though myogenin positivity is the more definitive of the two markers.\n    -   **Histomorphologic Equivocation:** The inability to definitively distinguish between embryonal and alveolar patterns on histomorphology is a significant source of uncertainty. This distinction has traditionally been a primary determinant of prognosis and treatment intensity.\n\n2.  **Prognostic and Therapeutic Stratification:** The single most important prognostic factor in RMS is the underlying genetic fusion status.\n    -   The term \"alveolar RMS\" is now largely replaced by a molecular classification. Tumors with a rearrangement of the FOXO1 gene, typically resulting in a PAX3-FOXO1 or PAX7-FOXO1 fusion oncogene, are classified as **fusion-positive RMS**. These tumors are associated with a significantly worse prognosis and require more aggressive, risk-stratified therapeutic protocols.\n    -   Tumors lacking this fusion are classified as **fusion-negative RMS**. This category includes most embryonal RMS and a subset of tumors that look \"alveolar\" by microscopy but lack the fusion. Fusion-negative RMS has a comparatively better prognosis, similar to that of conventional embryonal RMS.\n    -   Therefore, definitively establishing the FOXO1 fusion status is paramount for accurate risk stratification and for selecting the appropriate treatment regimen. An incorrect classification could lead to either under-treatment of a high-risk tumor or over-treatment (with its associated toxicities) of a lower-risk tumor.\n\n3.  **Adherence to Modern Classification Standards:** Contemporary cancer diagnosis, as reflected in the World Health Organization (WHO) classification of tumors, integrates histopathology, immunohistochemistry, and molecular genetics. For pediatric soft tissue sarcomas like RMS, molecular data are no longer just ancillary; they are integral to the definitive diagnosis. In a case with any degree of morphologic or immunophenotypic ambiguity, proceeding to molecular testing to confirm or rule out a defining genetic alteration like a FOXO1 rearrangement is the standard of care. This provides an objective, definitive basis for classification that transcends the subjective elements of microscopic interpretation.", "answer": "$$\\boxed{0.9760}$$", "id": "4445998"}, {"introduction": "Once a diagnosis of rhabdomyosarcoma is established, the next crucial step is risk stratification through clinical staging. The Tumor-Node-Metastasis (TNM) system provides a standardized framework for assessing disease extent, which directly informs treatment intensity. This practice connects the concrete task of staging with the radiobiological principles used to quantify treatment adjustments, illustrating how a higher stage translates into a biologically more potent therapy. [@problem_id:5200225]", "problem": "A pediatric patient presents with a soft tissue tumor in the calf. On physical examination and imaging, the maximal diameter is measured as $6 \\,\\mathrm{cm}$, and a sentinel lymph node biopsy reveals metastatic involvement. Comprehensive staging shows no evidence of distant metastasis on chest imaging and bone marrow evaluation. Using the Tumor-Node-Metastasis (TNM) system for rhabdomyosarcoma, classify the tumor according to the following well-tested facts: the tumor category $T$ is determined by largest diameter with $T_1$ if $\\leq 5 \\,\\mathrm{cm}$ and $T_2$ if $> 5 \\,\\mathrm{cm}$; the nodal category $N$ is $N_0$ if no regional nodal metastasis and $N_1$ if present; the metastasis category $M$ is $M_0$ if no distant metastasis and $M_1$ if present. For stage grouping in extremity rhabdomyosarcoma (an unfavorable site), use the widely accepted consolidation: Stage $2$ for $T_1 N_0 M_0$, Stage $3$ for any of $T_2$ with $M_0$ or $N_1$ with $M_0$, and Stage $4$ for $M_1$.\n\nBased on the stage determined, propose adjuvant radiotherapy intensification appropriate for node-positive, extremity disease by increasing the total dose from a baseline plan of $45 \\,\\mathrm{Gy}$ delivered in $1.8 \\,\\mathrm{Gy}$ fractions to an intensified plan of $50.4 \\,\\mathrm{Gy}$ delivered in $1.8 \\,\\mathrm{Gy}$ fractions, applying the Linear-Quadratic (LQ) radiobiological model with tumor $\\alpha/\\beta = 10 \\,\\mathrm{Gy}$. The biologically effective dose (BED) is defined by the well-tested formula\n$$\n\\mathrm{BED} = n d \\left( 1 + \\frac{d}{\\alpha/\\beta} \\right),\n$$\nwhere $n$ is the number of fractions, $d$ is the dose per fraction, and $\\alpha/\\beta$ is the tissue parameter.\n\nCompute two quantities:\n- the TNM stage group $S$ as an integer according to the grouping above, and\n- the intensification factor $I$ defined as the ratio of $\\mathrm{BED}$ for the intensified plan to the $\\mathrm{BED}$ for the baseline plan, $I = \\frac{\\mathrm{BED}_{\\mathrm{intensified}}}{\\mathrm{BED}_{\\mathrm{baseline}}}$.\n\nRound $I$ to $3$ significant figures. Report your final answer as a two-entry row vector $[S, I]$. The intensification factor $I$ is dimensionless; no units are required for the final reported values.", "solution": "The problem is validated as scientifically grounded, well-posed, and objective. All data and definitions required for a unique solution are provided and are consistent with established principles in pediatric oncology and radiation biology.\n\nThe problem requires the determination of two quantities: the TNM stage group, $S$, and the radiobiological intensification factor, $I$.\n\nFirst, we determine the TNM stage group, $S$. The patient's clinical and pathological findings are assessed against the provided staging rules.\n\n1.  **Tumor (T) Category**: The maximal tumor diameter is given as $6 \\,\\mathrm{cm}$. The rule states that the category is $T_1$ for diameters $\\leq 5 \\,\\mathrm{cm}$ and $T_2$ for diameters $> 5 \\,\\mathrm{cm}$. Since $6 \\,\\mathrm{cm} > 5 \\,\\mathrm{cm}$, the tumor category is $T_2$.\n\n2.  **Nodal (N) Category**: The problem states that a sentinel lymph node biopsy reveals metastatic involvement. The rule is $N_0$ for no regional nodal metastasis and $N_1$ if present. Therefore, the nodal category is $N_1$.\n\n3.  **Metastasis (M) Category**: The problem states there is no evidence of distant metastasis. The rule is $M_0$ for no distant metastasis and $M_1$ if present. Thus, the metastasis category is $M_0$.\n\nCombining these, the patient's full TNM classification is $T_2 N_1 M_0$.\n\nNext, we use the provided stage grouping rules for extremity rhabdomyosarcoma, which is an unfavorable site.\n- Stage $2$: $T_1 N_0 M_0$\n- Stage $3$: any of $T_2$ with $M_0$ or $N_1$ with $M_0$\n- Stage $4$: $M_1$\n\nThe patient's classification, $T_2 N_1 M_0$, satisfies the criteria for Stage $3$ because the tumor is $T_2$ and the distant metastasis status is $M_0$. It also satisfies the criteria through the nodal status, as it is $N_1$ with $M_0$. Consequently, the stage group is $S=3$.\n\nSecond, we compute the intensification factor, $I$. This is defined as the ratio of the Biologically Effective Dose (BED) of the intensified plan to that of the baseline plan, $I = \\frac{\\mathrm{BED}_{\\mathrm{intensified}}}{\\mathrm{BED}_{\\mathrm{baseline}}}$.\n\nThe formula for BED is given as:\n$$\n\\mathrm{BED} = n d \\left( 1 + \\frac{d}{\\alpha/\\beta} \\right)\n$$\nwhere $n$ is the number of fractions, $d$ is the dose per fraction, and $\\alpha/\\beta$ is the tissue-specific parameter.\nThe total dose $D$ is related to $n$ and $d$ by $D = n d$. We can rewrite the BED formula in terms of the total dose $D$:\n$$\n\\mathrm{BED} = D \\left( 1 + \\frac{d}{\\alpha/\\beta} \\right)\n$$\nThe given value for the tumor is $\\alpha/\\beta = 10 \\,\\mathrm{Gy}$.\n\nFor the baseline plan:\n- Total dose, $D_{\\mathrm{baseline}} = 45 \\,\\mathrm{Gy}$\n- Dose per fraction, $d_{\\mathrm{baseline}} = 1.8 \\,\\mathrm{Gy}$\nThe BED for the baseline plan is:\n$$\n\\mathrm{BED}_{\\mathrm{baseline}} = D_{\\mathrm{baseline}} \\left( 1 + \\frac{d_{\\mathrm{baseline}}}{\\alpha/\\beta} \\right) = 45 \\left( 1 + \\frac{1.8}{10} \\right) = 45 (1 + 0.18) = 45 \\times 1.18 = 53.1 \\,\\mathrm{Gy}_{10}\n$$\n\nFor the intensified plan:\n- Total dose, $D_{\\mathrm{intensified}} = 50.4 \\,\\mathrm{Gy}$\n- Dose per fraction, $d_{\\mathrm{intensified}} = 1.8 \\,\\mathrm{Gy}$\nThe BED for the intensified plan is:\n$$\n\\mathrm{BED}_{\\mathrm{intensified}} = D_{\\mathrm{intensified}} \\left( 1 + \\frac{d_{\\mathrm{intensified}}}{\\alpha/\\beta} \\right) = 50.4 \\left( 1 + \\frac{1.8}{10} \\right) = 50.4 (1 + 0.18) = 50.4 \\times 1.18 = 59.472 \\,\\mathrm{Gy}_{10}\n$$\n\nNow, we calculate the intensification factor $I$:\n$$\nI = \\frac{\\mathrm{BED}_{\\mathrm{intensified}}}{\\mathrm{BED}_{\\mathrm{baseline}}} = \\frac{50.4 \\times \\left( 1 + \\frac{1.8}{10} \\right)}{45 \\times \\left( 1 + \\frac{1.8}{10} \\right)}\n$$\nSince the dose per fraction $d$ is the same for both plans ($d_{\\mathrm{baseline}} = d_{\\mathrm{intensified}} = 1.8 \\,\\mathrm{Gy}$), the term $\\left( 1 + \\frac{1.8}{10} \\right)$ cancels out from the numerator and the denominator. The ratio simplifies to the ratio of the total physical doses:\n$$\nI = \\frac{D_{\\mathrm{intensified}}}{D_{\\mathrm{baseline}}} = \\frac{50.4}{45} = 1.12\n$$\nThe problem requires rounding $I$ to $3$ significant figures. The calculated value of $1.12$ already has exactly $3$ significant figures.\n\nThe two quantities are the stage group, $S = 3$, and the intensification factor, $I = 1.12$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n3 & 1.12\n\\end{pmatrix}\n}\n$$", "id": "5200225"}, {"introduction": "Effective local control with radiotherapy depends on the precise definition of treatment volumes that account for the visible tumor, potential microscopic spread, and geometric uncertainties. This hands-on practice simulates the essential steps a radiation oncologist takes, translating post-chemotherapy imaging into a final Planning Target Volume (PTV). You will apply standard margin recipes to progress from the Gross Tumor Volume (GTV) to the Clinical Target Volume (CTV) and ultimately to the PTV, providing a practical understanding of how treatment plans are constructed. [@problem_id:5200181]", "problem": "A $5\\,\\text{cm}$ bladder mass with heterogeneous enhancement on Magnetic Resonance Imaging (MRI) is found in a $6$-year-old child and is clinically suspected to be pediatric rhabdomyosarcoma based on location, age, and imaging characteristics. The lesion is centered in the bladder dome and projects intraluminally; there is no gross extravesical extension on MRI. The longest diameter is craniocaudal ($d_{1} = 5.0\\,\\text{cm}$), with orthogonal transverse ($d_{2} = 3.5\\,\\text{cm}$) and anteroposterior ($d_{3} = 3.0\\,\\text{cm}$) diameters. The initial management plan includes neoadjuvant chemotherapy with vincristine, actinomycin D, and cyclophosphamide (VAC) for $12$ weeks, followed by definitive local therapy.\n\nYou are asked to address two tasks grounded in first principles and well-tested definitions:\n\n1. Briefly outline the next steps for biopsy planning that minimize tumor seeding and optimize histopathologic diagnosis within pediatric standards of care, considering the lesionâ€™s intravesical location and the need for local staging.\n\n2. After $12$ weeks of VAC, the mass demonstrates a uniform linear shrinkage factor $s = 0.6$ in each principal axis relative to the initial diameters. For radiotherapy planning, use the following clinically realistic and axis-specific rules to construct planning volumes from first principles:\n   - Define the Gross Tumor Volume (GTV) post-chemotherapy by scaling each initial diameter by $s$ and converting to semi-axes.\n   - Account for microscopic disease by expanding to the Clinical Target Volume (CTV) with an anisotropic margin consistent with bladder rhabdomyosarcoma: add $1.0\\,\\text{cm}$ along the craniocaudal axis, $1.0\\,\\text{cm}$ along the transverse axis, and $0.5\\,\\text{cm}$ along the anteroposterior axis.\n   - Account for setup uncertainty and internal motion by expanding from CTV to Planning Target Volume (PTV) using axis-specific margin components based on a conservative coverage criterion (ensuring high probability of adequate dose coverage): for craniocaudal, systematic error $\\Sigma_{1} = 0.2\\,\\text{cm}$ and random error $\\sigma_{1} = 0.3\\,\\text{cm}$; for transverse, $\\Sigma_{2} = 0.2\\,\\text{cm}$ and $\\sigma_{2} = 0.2\\,\\text{cm}$; for anteroposterior, $\\Sigma_{3} = 0.3\\,\\text{cm}$ and $\\sigma_{3} = 0.3\\,\\text{cm}$. Combine these to produce axis-specific PTV margins using a conservative, empirically validated margin-construction approach founded on Gaussian error propagation and coverage quantiles.\n   - Model all volumes as ellipsoids aligned with the three axes.\n\nCompute the final PTV volume after chemotherapy and margin expansions. Express the final volume in $\\text{cm}^{3}$ and round your answer to $4$ significant figures.", "solution": "The problem presented is a valid, well-posed, and scientifically grounded exercise in applied medical physics and oncology. It provides a clinically realistic scenario and all necessary parameters to perform the requested tasks. The problem is divided into two parts: a qualitative outline of clinical procedure and a quantitative calculation of a radiotherapy planning volume.\n\n**Part 1: Biopsy Planning**\n\nThe first task is to outline the next steps for biopsy planning. For a $6$-year-old child with an intravesical mass suspicious for rhabdomyosarcoma, the primary goals are to obtain a definitive histopathologic diagnosis and perform initial local staging while strictly minimizing the risk of tumor cell spillage or seeding. The standard-of-care approach is a transurethral resection of the bladder tumor (TURBT) performed by a pediatric urologist or surgical oncologist with expertise in sarcoma. This approach is optimal for several reasons. Firstly, it provides access to the intraluminal lesion via a natural orifice, completely avoiding a trans-abdominal or percutaneous needle tract that would breach tissue planes and create a high risk of seeding malignant cells into the peritoneum or abdominal wall, which would significantly upstage the patient and complicate subsequent treatment. Secondly, the TURBT allows for the procurement of sufficient tissue for a comprehensive pathologic evaluation, which must include not only routine histology (for morphology and grading) but also fresh tissue for molecular and cytogenetic analysis (e.g., testing for PAX-FOXO1 fusion status), as this is a critical prognostic factor that dictates treatment intensity. Finally, the procedure serves a staging function. The surgeon can assess and document the lesion's size, location relative to bladder landmarks (e.g., trigone, ureteric orifices), and attempt to determine the depth of invasion into the bladder wall, which is essential information for the definitive tumor, nodes, metastasis (TNM) staging. The procedure must be coordinated within a multidisciplinary team including pediatric oncology, pathology, and radiation oncology to ensure all diagnostic and staging requirements are met.\n\n**Part 2: Planning Target Volume (PTV) Calculation**\n\nThe second task is to compute the Planning Target Volume (PTV) after $12$ weeks of chemotherapy. The calculation proceeds sequentially through the definition of the Gross Tumor Volume (GTV), Clinical Target Volume (CTV), and finally the PTV. All volumes are modeled as ellipsoids, for which the volume $V$ is given by $V = \\frac{4}{3}\\pi abc$, where $a$, $b$, and $c$ are the semi-axes.\n\nFirst, we determine the dimensions of the post-chemotherapy GTV. The initial diameters are given as $d_{1,init} = 5.0\\,\\text{cm}$ (craniocaudal), $d_{2,init} = 3.5\\,\\text{cm}$ (transverse), and $d_{3,init} = 3.0\\,\\text{cm}$ (anteroposterior). The mass undergoes a uniform linear shrinkage by a factor of $s = 0.6$. The post-chemotherapy diameters are:\n$$d_{1,post} = s \\cdot d_{1,init} = 0.6 \\cdot 5.0\\,\\text{cm} = 3.0\\,\\text{cm}$$\n$$d_{2,post} = s \\cdot d_{2,init} = 0.6 \\cdot 3.5\\,\\text{cm} = 2.1\\,\\text{cm}$$\n$$d_{3,post} = s \\cdot d_{3,init} = 0.6 \\cdot 3.0\\,\\text{cm} = 1.8\\,\\text{cm}$$\nThe GTV corresponds to this post-chemotherapy residual mass. The semi-axes of the GTV are half of these diameters:\n$$a_{GTV} = \\frac{d_{1,post}}{2} = \\frac{3.0}{2}\\,\\text{cm} = 1.5\\,\\text{cm}$$\n$$b_{GTV} = \\frac{d_{2,post}}{2} = \\frac{2.1}{2}\\,\\text{cm} = 1.05\\,\\text{cm}$$\n$$c_{GTV} = \\frac{d_{3,post}}{2} = \\frac{1.8}{2}\\,\\text{cm} = 0.9\\,\\text{cm}$$\n\nNext, we determine the dimensions of the CTV by adding the specified anisotropic margins for microscopic disease to the GTV semi-axes. The margins are $m_{CTV,1} = 1.0\\,\\text{cm}$, $m_{CTV,2} = 1.0\\,\\text{cm}$, and $m_{CTV,3} = 0.5\\,\\text{cm}$.\n$$a_{CTV} = a_{GTV} + m_{CTV,1} = 1.5\\,\\text{cm} + 1.0\\,\\text{cm} = 2.5\\,\\text{cm}$$\n$$b_{CTV} = b_{GTV} + m_{CTV,2} = 1.05\\,\\text{cm} + 1.0\\,\\text{cm} = 2.05\\,\\text{cm}$$\n$$c_{CTV} = c_{GTV} + m_{CTV,3} = 0.9\\,\\text{cm} + 0.5\\,\\text{cm} = 1.4\\,\\text{cm}$$\n\nFinally, we construct the PTV by adding a margin to the CTV to account for geometric uncertainties (setup errors and internal motion). The problem specifies using a \"conservative, empirically validated margin-construction approach founded on Gaussian error propagation and coverage quantiles.\" This unequivocally refers to the widely adopted van Herk margin formula, which combines systematic errors ($\\Sigma$) and random errors ($\\sigma$) to ensure $90\\%$ of patients receive at least $95\\%$ of the prescribed dose to the CTV. The formula is $M = 2.5\\Sigma + 0.7\\sigma$. We apply this formula for each axis.\n\nFor the craniocaudal axis ($1$): $\\Sigma_{1} = 0.2\\,\\text{cm}$, $\\sigma_{1} = 0.3\\,\\text{cm}$.\n$$m_{PTV,1} = 2.5\\Sigma_{1} + 0.7\\sigma_{1} = 2.5(0.2\\,\\text{cm}) + 0.7(0.3\\,\\text{cm}) = 0.5\\,\\text{cm} + 0.21\\,\\text{cm} = 0.71\\,\\text{cm}$$\nFor the transverse axis ($2$): $\\Sigma_{2} = 0.2\\,\\text{cm}$, $\\sigma_{2} = 0.2\\,\\text{cm}$.\n$$m_{PTV,2} = 2.5\\Sigma_{2} + 0.7\\sigma_{2} = 2.5(0.2\\,\\text{cm}) + 0.7(0.2\\,\\text{cm}) = 0.5\\,\\text{cm} + 0.14\\,\\text{cm} = 0.64\\,\\text{cm}$$\nFor the anteroposterior axis ($3$): $\\Sigma_{3} = 0.3\\,\\text{cm}$, $\\sigma_{3} = 0.3\\,\\text{cm}$.\n$$m_{PTV,3} = 2.5\\Sigma_{3} + 0.7\\sigma_{3} = 2.5(0.3\\,\\text{cm}) + 0.7(0.3\\,\\text{cm}) = 0.75\\,\\text{cm} + 0.21\\,\\text{cm} = 0.96\\,\\text{cm}$$\n\nThese margins are added to the CTV semi-axes to obtain the PTV semi-axes:\n$$a_{PTV} = a_{CTV} + m_{PTV,1} = 2.5\\,\\text{cm} + 0.71\\,\\text{cm} = 3.21\\,\\text{cm}$$\n$$b_{PTV} = b_{CTV} + m_{PTV,2} = 2.05\\,\\text{cm} + 0.64\\,\\text{cm} = 2.69\\,\\text{cm}$$\n$$c_{PTV} = c_{CTV} + m_{PTV,3} = 1.4\\,\\text{cm} + 0.96\\,\\text{cm} = 2.36\\,\\text{cm}$$\n\nThe volume of the PTV ellipsoid is computed using these semi-axes:\n$$V_{PTV} = \\frac{4}{3}\\pi \\cdot a_{PTV} \\cdot b_{PTV} \\cdot c_{PTV}$$\n$$V_{PTV} = \\frac{4}{3}\\pi (3.21\\,\\text{cm})(2.69\\,\\text{cm})(2.36\\,\\text{cm})$$\n$$V_{PTV} = \\frac{4}{3}\\pi (20.378364\\,\\text{cm}^3) \\approx 85.35904\\,\\text{cm}^3$$\n\nRounding the final result to $4$ significant figures as requested gives $85.36\\,\\text{cm}^3$.", "answer": "$$\\boxed{85.36}$$", "id": "5200181"}]}